Markets

Honey Badger Silver Inc. successfully closed the first tranche of its private placement, raising approximately $2.01 million. The financing, involving non-flow-through units and flow-through shares, will fund exploration on properties in the Yukon, Northwest Territories, and Nunavut, as well as property advancement and acquisitions. Prominent investor Eric Sprott participated in the round.

Gree Electric’s leader Dong Mingzhu prioritizes domestically cultivated talent, citing national interests. She emphasizes mindset, innovation, and responsibility over age or origin. Marketing Director Zhu Lei clarifies Gree values loyalty, diligence, and contribution, not foreign vs. domestic status once hired. The company seeks “hard workers” and “doers” aligned with its ethos.

Huawei’s Terminal BG announced new HarmonyOS 5 games, prompting user inquiries about Genshin Impact’s arrival. Huawei confirmed active development and technical discussions with developers, advising users to wishlist the game and expect notifications upon launch. MiHoYo, Genshin Impact’s developer, is recruiting beta testers for a HarmonyOS version. Huawei aims for 100,000 HarmonyOS applications this year to strengthen its ecosystem.

QT Imaging Holdings, Inc. announced its 2025 virtual Annual Meeting of Stockholders, scheduled for August 19, 2025. Registered shareholders as of July 16, 2025, are eligible to vote. Details for the webcast are available in the proxy statement and on the company’s website. QT Imaging is an innovator in medical imaging technology, focusing on low-frequency sound waves for disease detection and treatment.

Gree Electric’s Market Director, Zhu Lei, stated that Gree’s focus on technological advancement, rather than price wars, has stabilized the air conditioning market for over 30 years. He contrasted this with other sectors experiencing intense competition and criticized brands that prioritize crushing rivals over sustainable profits. Lei urged Chinese manufacturers to uphold “Made in China” and lead collaboratively.

Butler National Corporation reported record earnings of $0.19 per share and a 27% year-over-year surge in operating income to $16.8 million for fiscal year 2025. The company saw strong performance in its Aerospace Products segment, with revenue up 15%, driven by new aircraft modifications and increased deliveries. The Professional Services segment remained stable. Butler National also announced strategic investments in new product development and expansion of fabrication capabilities.

Liberty Energy Inc. (NYSE: LBRT) will release its second-quarter financial results after market close on Wednesday, July 23, 2025. The company will host a conference call to discuss its performance on Thursday, July 24, 2025. Liberty is a leading North American provider of completion services and technologies, also investing in power and storage solutions.

Monte Rosa Therapeutics’ AI platform, QuEEN™, has identified a vast array of human proteins targetable by molecular glue degraders (MGDs). Published in *Science*, this breakthrough significantly expands the universe of “undruggable” therapeutic targets, particularly for MGDs via cereblon. The company is integrating these AI-driven insights to accelerate its pipeline of novel MGD medicines, aiming to transform patient outcomes in oncology, immunology, and inflammation.

CoreWeave, the AI Hyperscaler, announces it is the first AI cloud provider to deploy NVIDIA’s latest GB300 NVL72 systems, promising significant performance boosts for AI reasoning and agentic workloads. This strategic move, supported by partnerships with Dell, Switch, and Vertiv, reinforces CoreWeave’s commitment to offering state-of-the-art AI infrastructure for global innovators.

Hemostemix’s ACP-01 therapy, a novel cellular treatment for heart failure, has been detailed in a peer-reviewed paper. Targeting non-ischemic dilated cardiomyopathy, ACP-01 utilizes autologous cells to combat inflammation, fibrosis, and improve blood flow. Earlier studies showed significant improvement in cardiac function, with LVEF increases up to 47.1% in DCM patients. The therapy is now available in Florida under new legislation, offering a promising option for patients with limited alternatives.